8-K: Curis Faces Nasdaq Delisting Over Bid Price Deficiency

Curis, Inc. has received a delisting notice from Nasdaq due to its common stock closing below the $1.00 minimum bid price requirement for 30 consecutive business days.

Summary

• Curis, Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026.
• The company failed to maintain the minimum $1.00 per share bid price requirement for 30 consecutive business days.
• Trading is scheduled to be suspended on May 6, 2026, unless the company appeals.
• The company is currently under a one-year Discretionary Panel Monitor initiated on February 3, 2026.
• Management intends to request a hearing before the Nasdaq Hearings Panel by May 4, 2026, to stay the delisting process.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, as the threat of delisting combined with existing regulatory monitoring significantly increases the risk profile for investors.

Positives

• The company is actively exercising its right to appeal the delisting determination to maintain its Nasdaq listing.

Negatives

• The company is in violation of Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price.
• The company is already subject to a Discretionary Panel Monitor, which limits its ability to provide standard compliance plans for new deficiencies.
• The threat of suspension from the Nasdaq Capital Market creates significant uncertainty for shareholders.

Risks

• Potential delisting from the Nasdaq Capital Market if the appeal is unsuccessful.
• Loss of liquidity and potential negative impact on share price due to delisting.
• Heightened regulatory scrutiny due to the existing Discretionary Panel Monitor.
• Inability to regain compliance with Nasdaq listing standards within the required timeframe.

Future Outlook

The company intends to appeal the delisting determination by requesting a hearing before the Nasdaq Hearings Panel, which would stay the delisting process pending the outcome of the hearing.

Management Comments

• The company intends to make a timely request for a new hearing with the initial Panel or a newly convened Panel to stay any further delisting actions.

Industry Context

StockSavvy.ai notes that small-cap biotechnology firms frequently face Nasdaq bid price compliance challenges during periods of clinical trial uncertainty or market volatility. The existence of a prior Discretionary Panel Monitor suggests the company is already in a precarious regulatory position compared to peers.

Comparison to Industry Standards

• The company's struggle to maintain a $1.00 share price is a common hurdle for micro-cap biotech companies in the development stage.
• The 'Discretionary Panel Monitor' status indicates a higher level of regulatory oversight than typical companies facing standard 180-day compliance periods.

Legal Proceedings

• The company is currently subject to a Discretionary Panel Monitor by Nasdaq.

Stakeholder Impact

• Shareholders face potential loss of liquidity if the stock is delisted to the OTC markets.
• The company's ability to raise capital may be impaired by the delisting threat.

Next Steps

• Submit a formal request for a hearing to the Nasdaq Hearings Panel by May 4, 2026.
• Prepare for the hearing process to present a case for continued listing.

Key Dates

Recommendation

The combination of a delisting notice and an existing regulatory monitor indicates severe operational and financial distress, making the stock highly speculative and risky for institutional investors.

Keywords

Nasdaq, delisting, Curis, CRIS, bid price, compliance, biotech